The rise in outsourcing is a positive development for the research antibodies and reagents market. By outsourcing the development and production of antibodies and reagents, companies can reduce costs, increase efficiency, access expertise, and increase flexibility, thus creating opportunities in the research antibodies and reagents market. Also, an increasing number of local players in emerging markets, such as China, India, and Mexico, are offering their research antibodies and reagents products at lower prices than established market players. As a result, the pricing pressure on established players has increased, who are being compelled to adopt competitive pricing strategies to maintain their market shares and this is challenging market growth.
The report Research Antibodies & Reagents
Market
are projected to reach USD 16.2 billion by 2028 from USD 11.8 billion in 2023,
at a CAGR of 6.5% during the forecast period.
Download PDF Brochure: -
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=94212793
Key Market
Dynamics:
Growth Drivers
- Increasing
research activity and funding for R&D
- Growing
industry-academia collaboration
Growth Opportunities
- Emerging
markets
- Personalized
medicine and protein therapeutics
- Growth in
stem cell and neurobiology research
- Increasing
focus on biomarker discovery
- Rising
interest in outsourcing
Challenges
- Cost and
time-intensive antibody development processes
- Pricing
pressure faced by prominent market players.
Trends
- Increasing
research on therapeutic antibodies
- Recombinant
antibodies supporting the smooth transition from in vitro to in vivo
- Growing
consolidation of the life sciences market for antibodies and reagents
Market Segmentation: -
On the basis of the product, the research antibodies
and reagents market are segmented into reagents and antibodies. The antibodies
segment is expected to grow at highest CAGR in forecast periods (2023-2028).
Antibodies are essential for routine procedures, such as western blotting, flow
cytometry, IHC, and ELISA.
On the basis of form, the research-use antibodies
are categorized into monoclonal, polyclonal, and recombinant antibodies. The
monoclonal antibodies segment accounted for the largest share of the research
antibodies market by form in 2022.
On the Basis of type, the research reagents market
are segmented into media &sera, stains & dyes, fixatives, buffers,
solvents, enzymes, probes, and other reagents. In 2022, the media & sera
reagent segment held the largest share of the global research reagents market.
On the basis of technology, the research antibodies
and reagents market are segmented into ELISA, flow cytometry, western blotting,
Immunohistochemistry, Immunofluorescence, Immunoprecipitation, and other
technologies. In 2022, the Enzyme-linked Immunosorbent Assay (ELISA) segment
accounted for the largest share of the market.
On the basis of application, the research antibodies
and reagents market are segmented into proteomics, drug development and
Genomics. In 2022, the proteomics segment accounted for the largest share.
On the basis of end user, the research antibodies
and reagents market are segmented into the pharmaceutical & biotechnology
companies, research labortories, and Contract Research Organizations. The
research laboratories segment accounted for the largest share of the market in
2022.
Regional Analysis:
The European market is expected to have the second
largest market share in 2022. The growth of the overall market in Europe is
attributed to an increase in R&D activities, rising government funding for
drug discovery research, and increasing growth in the pharmaceutical &
biological industries. In Europe, proteomics and genomics research for cancer
and neurobiological diseases have increased in the last decade. between
universities that are designed to promote excellence in research and education.
Recent
Developments of Research Antibodies & Reagents Industry
- In August 2023, Danaher (US)
entered into a definitive agreement to acquire all the outstanding shares
of Abcam plc (UK). Through this development, Abcam is expected to operate
as a standalone operating company within Danaher’s Life Sciences segment.
- In August 2023, Agilent
Technologies, Inc. (US) announced the opening of a new full-scale
Integrated Biology Center located at Monash University in Malaysia. The
facility is focused on building local capabilities to accelerate research
and development (R&D) in life science research.
- In June 2023, Cell Signaling
Technology, Inc. (US) and Lunaphore Technologies SA (Switzerland) have
decided to partner to integrate CST antibodies into Lunaphore's COMET
platform for Spatial Biology research.
Request For Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=94212793
Top Key Players: -
The prominent market players are Abcam plc (UK),
Cell Signaling Technology, Inc. (US), Thermo Fisher Scientific Inc. (US), Merck
KGaA (Germany), BD (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche
Ltd (Switzerland), Agilent Technologies, Inc. (US), Danaher (US), Lonza
(Switzerland), GenScript (China), and Revvity (US).
Related News:
